30-Day Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement: Intrepid TMVR Early Feasibility Study Results.

MLA

Zahr, Firas, et al. “30-Day Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement: Intrepid TMVR Early Feasibility Study Results.” JACC. Cardiovascular Interventions, vol. 15, no. 1, Jan. 2022, pp. 80–89. EBSCOhost, https://doi.org/10.1016/j.jcin.2021.10.018.

APA

Zahr, F., Song, H. K., Chadderdon, S. M., Gada, H., Mumtaz, M., Byrne, T., Kirshner, M., Bajwa, T., Weiss, E., Kodali, S., George, I., Heiser, J., Merhi, W. M., Thaden, J. J., Zhang, A., Lim, D. S., Reardon, M. J., Adams, D. H., Mack, M. J., & Leon, M. B. (2022). 30-Day Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement: Intrepid TMVR Early Feasibility Study Results. JACC. Cardiovascular Interventions, 15(1), 80–89. https://doi.org/10.1016/j.jcin.2021.10.018

Chicago

Zahr, Firas, Howard K Song, Scott M Chadderdon, Hemal Gada, Mubashir Mumtaz, Timothy Byrne, Merick Kirshner, et al. 2022. “30-Day Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement: Intrepid TMVR Early Feasibility Study Results.” JACC. Cardiovascular Interventions 15 (1): 80–89. doi:10.1016/j.jcin.2021.10.018.